[1]
Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.R.M.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M.F.; Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kumar, H.M.C.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muqbil, I.; Muralidhar, V.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rpasinghe, V.H.P.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Vander, M.G.; Venkateswaran, V.; Dass, S. A broad-spectrum integrative design for cancer prevention and therapy. Semin. Cancer Biol., 2015, 35, 276-304.
[2]
Block Keith, I. Life over cancer: The Block Cancer Program for Integrative Cancer Treatment; Bantam: USA, 2009.
[3]
Wei, J.Y.; Huang, W.H.; Du, C.W.; Qui, S.Q.; Wei, X.L.; Liu, J.; Zhang, G.J. Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China. Sci. Rep., 2014, 4, 5360.
[6]
Heikkila, K.; Nyberg, S.T.; Madsen, I.E.; DeVroom, E.; Alfredssons, L.; Bjorner, J.J.; Borritz, M.; Burr, H.; Erbel, R.; Ferrie, J.E.; Fransson, E.I.; Geuskens, G.A.; Hooftman, W.E.; Houtman, I.L.; Ckel, K.J.; Knutsson, A.; Koskenvuo, M.; Lunau, T.; Nielsen, M.L.; Nordin, M.; Oksanen, T.; Pejtersen, J.H.; Pentti, J.; Shipley, M.J.; Steptoe, A.; Suominen, M.; Oksanen, T.; Pejtersen, J.H.; Pentti, J.; Shipley, M.J.; Steptoe, A.; Suominen, S.B.; Theorell, T.; Vahtera, J.; Westerholm, P.J.M.; Westerlund, H.; Dragano, N.; Rugulies, R.; Kawachi, I.; Batty, G.D.; Manoux, A.S.; Virtanen, M.; Kivima, M. Long working hours and cancer risk: A multi-cohort study.
Br. J. Cancer, 2016,
114, 813-818.
[
http://dx.doi.org/10.1136/oemed-2016-103951.358]
[9]
Koga, H.; Sakisaka, S.; Harada, M.; Takagi, T.; Hanada, S.; Taniguchi, E.; Kawaguchi, T.; Sasatomi, K.; Kimura, R.; Hashimoto, O.; Uena, T.; Yano, H.; Kojiro, M.; Sata, M. Involvement of p21WAF1/Cip1, p27Kip1and p18INK4c in troglitazone-induced cell cycle arrest in human hepatoma cell lines. Hepatology, 2001, 33(5), 1087-1097.
[10]
Fan, Y.H.; Chen, A.; Natarajan, Y.; Guo, F.; Harbinski, J.; Iyasere, W.; Christ, H.; Aktas, J.A. Structure activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg. Chem. Med. Lett., 2004, 14, 2547-2550.
[12]
Reiser, M.; Schnell, R.; Straub, G.; Borchmann, P.; Wilhelm, M.; Übelacker, R.; Wörmann, B.; Münch, R.; Diehl, V.; Engert, A. Dize (Dexamethasone, idarubicin and contious infusion of ifosfamide and etoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk. Lymphoma, 1998, 31, 359-366.
[15]
Panigrahy, D.; Singer, S.; Shen, Q.L.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; Fletcher, J.A.; Hlatky, L.; Hahnfeldt, P.; Folkman, J.; Kaipainen, A. PPARᵧ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest., 2002, 110(7), 923-932.
[17]
Patil, V.; Tilekar, K.; Mehendale, M.S.; Mohan, R.; Ramaa, C.S. Synthesis and primary cytotoxicity of new 5- benzylidene-2, 4-thiazolidinedione derivatives. Eur. J. Med. Chem., 2010, 45, 4539-4544.
[19]
Madhuri, M.; Prasad, C.; Avupati, V.R. In silico protein-ligand docking studies on thiazolidinediones as potential anticancer agents. Int. J. Comput. Appl., 2014, 95, 975-8887.
[20]
Yan, K.; Yao, C.; Chang, H.; Lai, G.; Cheng, A.; Chuang, S. The synergistic anticancer effect of troglitazone combined with asprin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol. Carcinog., 2010, 49, 235-246.
[21]
Chinthala, Y.; Domatti, A.K.; Sarfaraz, A.; Singh, S.P.; Arigari, N.K.; Gupta, N.; Satya, K.V.N.; Kumar, J.K.; Khan, F.; Tiwari, A.K.; Paramjit, G. Synthesis, biological evaluation and molecular docking studies of some novel thiazolidinediones with triazole ring. Eur. J. Med. Chem., 2013, 70, 308-314.
[22]
Asati, V.; Mahapatra, D.K.; Bharti, S.K. Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. Eur. J. Med. Chem., 2014, 87, 814-833.
[23]
Sharma, P.; Reddy, T.S.; Thummuri, D.; Senwar, K.R.; Kumar, N.P.; Naidu, V.G.M.; Bhargava, S.K.; Shankaraiah, N. Synthesis and biological evaluation of new benzimidazole-thiazoldinedione hybrids as potential cytotoxic and apoptosis inducing agents. Eur. J. Med. Chem., 2016, 124, 608-621.
[24]
Barreto, M.J.; Galdino, M.L.; Pereira, D.T.M.; Cruz, J.; Rabello, M.M.; Alves, M.C.; Hernandes, M.Z.; Pitta, I.R.; Galdino, S.L.; Galdino, M. Synthesis, in vitro anticancer activity and in silico study of new disubstituted thiazolidinedione derivatives. Med. Chem. Res., 2014, 23, 3220-3226.
[25]
Bahare, R.S.; Ganguly, S.; Choowongkomon, K.; Seetaha, S. Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted –benzylidine-2,4-thiazolidinediones. DARU. J. Pharm. Sci, 2015, 23(6), 1-15.
[26]
Youssef, A.M.; White, M.S.; Villanueva, E.B.; El-Ashmawy, I.M.; Klegeris, A. Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorg. Med. Chem., 2010, 18, 2019-2028.
[28]
Darwish, K.M.; Salama, I.; Mostafa, S.M.; Gomaa, M.S.; Helal, M.A. Design, synthsis and biological evaluation of novel thiazolidinediones as PPARᵧ-FFAR1 dual agonists. Eur. J. Med. Chem., 2016, 109, 157-172.
[29]
Costa, V.; Paonessa, F.; Chiefari, E.; Palaia, L.; Brunetti, G.; Gulletta, E.; Fusco, A.; Brunetti, A. The insulin receptor: A new anticancer target for peroxisome proliferator-activated receptor-ᵧ (PPARᵧ) and thiazolidinedione- PPARᵧ agonists. Endocr. Relat. Cancer, 2008, 15, 325-335.
[30]
Jain, V.S.; Vora, D.K.; Ramaa, C.S. Thiazolidine-2,4-diones: Progress towards multifarious applications. Bioorg. Med. Chem., 2013, 21, 1599-1620.
[31]
Hiatt, W.R.; Kaul, S.; Smith, R.J. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N. Engl. J. Med., 2013, 369, 1285-1287.
[33]
Hossain, S.U.; Bhattacharya, S. Synthesis of O-plenylated derivatives of 5-benzylidene-2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase II antioxidant/detoxifying enzymes. Bioorg. Med. Chem., 2007, 17, 1149-1154.
[34]
Min, G.; Lee, S.; Kim, H.; Han, Y.; Lee, R.; Jeong, D.G.; Han, D.C.; Kwon, B. Rhodamine-based PL3-inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg. Med. Chem. Lett., 2013, 23, 3769-3774.
[35]
Chen, H.; Fan, Y.; Natarajan, A.; Guo, Y.; Iyasere, J.; Harbinski, F.; Luus, L.; Christ, W.; Aktas, H.; Halperin, J.A. Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg. Med. Chem. Lett., 2004, 14, 5401-5405.
[36]
Geetha, B.; Swarnalatha, G.; Subba, R.G. Biological evaluation of synthesized thiazolidinedione derivatives for antidiabetic activity on STZ caused diabetes in rat. Int. J. Res. Sci., 2019, 10, 1042-1048.
[39]
Christopher, M.L.; Donna, M.K.; Kieu, C.D.; Marcie, J.G.; Cindy, L.T.; Leah, A.D.; Thomas, H.M.; Christine, A.S.; Steven, A.B. Rotiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis, 2009, 30, 2095-2099.
[41]
Govindarajan, R.; Ratnasinghe, L.; Simmons, D.L.; Siegel, E.R.; Midathada, M.V.; Kim, L.; Kim, P.J.; Owens, R.J.; Lang, N.P. Thiazolidinediones and the risk of lung, prostate and colon cancer in patients with diabetes. J. Clin. Oncol., 2007, 25, 1476-1481.
[43]
Benson, A.B.; Venool, A.P.; Cederquist, L.; Chan, E.; Chen, Y.; Cooper, H.S.; Deming, D.; Engstrom, P.F.; Enziger, P.C.; Fichera, A.; Grem, J.L.; Grothey, A.; Hochster, H.S.; Hoffe, S.; Hunt, S.; Kamel, A.; Kirilcuk, N.; Krishnamurthi, S.; Messersmith, W.A.; Mulcahy, M.F.; Murphy, J.D.; Nurkin, S.; Saltz, L.; Sharma, S.; Shibata, D.; Skibber, J.M. Colon cancer 1, 2017. Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2017, 15(3), 370-398.
[49]
Sakat, S.; Preeti, T.; Juvekar, A. In vitro anti-inflammatory activity of aqueous and methanol extracts of Erythrina indica Lam leave. Pharmacologyonline, 2009, 3, 221-229.
[54]
Hassan, M.F.; Rauf, A. Synthesis and the study on the binding of the thiazol-2(3H) ylidine derivative with human serum albumin using spectroscopic and molecular docking methods. Luminescence, 2017, 32, 602-612.
